EyePoint Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Got it. All right. Good afternoon, everyone. Thank you for joining. My name is Pascal Kashi, I'm one of the Senior Biotech Analysts at Jefferies. We're here in London at the Jefferies Global Healthcare Conference. Really pleased to have this today, the management team of EyePoint, joined by Dr. Jay Duker and George Elston, CEO and CFO, respectively, of the company. Jay, could you just kick us off with a little bit of an intro to the company?
Of course, and thanks very much for inviting us. We're really happy to be here. EyePoint is a drug delivery company to the back of the eye. Our lead asset is called DURAVYU. DURAVYU is the combination of a small molecule tyrosine kinase inhibitor called vorolanib. Vorolanib has activity against all the VEGF receptors, as well as PDGF, and as well as JAK1, giving it an anti-inflammatory component. It's in our patented delivery system, and the sustained release delivery system is able to deliver the drug with an intravitreal injection to last at least six months or longer in almost all patients. The drug is shipped and stored at room temperature, and the inserts are now created so that they're 95% drug, only 6% matrix, and the matrix is fully bioerodible.
We're currently still essentially in four phase III trials, two in wet AMD and two in diabetic macular edema, DME. Although, I'm sure people who've been following us know that we've reported on the top line of the wet AMD trials, the first one in August and the second one in October. And while the secondary endpoints look quite good, the primary endpoints in both trials were missed. As a result, we're in the process of closing the wet AMD trials and going forward as a DME-only company for the time being.
Got it. Can you talk to us about, we'll get into more specifics, but just starting high level, what gives you confidence in DME after the wet AMD experience?
Sure. DME, while a VEGF-mediated disease, is a different pathophysiology. DME is created by damage to the retinal blood vessels that result in their leakage. Wet AMD is the growth of new blood vessels from the choroid, the level below the retina, and probably inflammation plays more of a role than ischemia does. We know that wet AMD is primarily a VEGF-mediated disease. Anti-VEGFs control the disease and fluid quite rapidly, whereas in DME, the responses are variable. In fact, if you look at the label, for example, two milligram EYLEA in wet AMD, it's a three-injection monthly load followed by every other month. It's five-injection load in DME, I think confirming that it takes more treatment time to see improvement in DME. Also, this whole inflammatory component for DME has been known for many years. Intravitreal corticosteroids work quite well in diabetic macular edema.
In fact, studies that are done in eyes that are already pseudophakic, meaning they've had cataract surgery already, show similar results with intravitreal steroids as they do with anti-VEGFs. Just recently, Merck showed data for their Wnt agonist, which was non-inferior in DME to LUCENTIS. The point being that drugs that don't primarily affect the VEGF pathway can be successful in DME. That's the first part, I would say, is pathophysiologically. Secondly, we've got some pretty good preclinical data and some indirect clinical data that our drug, vorolanib, has an anti-inflammatory effect through JAK1 receptor, which blocks the downstream effects of IL-6. IL-6 is the cytokine that's been implicated in the inflammation in DME. It doesn't play nearly as big a role in wet AMD.
Again, we've shown in preclinical models that vorolanib at doses that we're achieving in humans is able to show that anti-inflammatory aspect. In humans, we studied DME in our phase II VERONA trial. The VERONA trial enrolled only patients who had active DME, meaning they had decreased vision and they had fluid on optical coherence tomography. The study results showed that at the end of the trial, 24 weeks, against EYLEA 2 milligrams, we were non-inferior. Both groups gained about seven letters. However, the fluid control was significantly better in the DURAVYU arm, and the fluid control and the vision gains were better at week four. As early as week four, the DURAVYU eyes had better vision and drier retinas than did the EYLEA arm. These results really give us confidence, along with some of the other secondary endpoints.
For example, we looked at leakage from the capillaries. That can be looked at in a quantitative fashion using fluorescein angiography. In a dose-dependent fashion, the DURAVYU eyes had less leakage than did the EYLEA eyes at the end of the trial. If you just ask the binary question at the end of the trial, was there still diabetic macular edema present or not, about half of the DURAVYU eyes had no DME at the end of the trial, where 100% of the control eyes still had some degree of DME. Those findings, I think, really also give us confidence in the DME result. I'll go back to the wet AMD result. I mentioned the secondary endpoints, and we did, I think, remarkably well with the secondary endpoints. First of all, with safety, we dosed almost 450 patients with repeat dosing.
The patients got dosed every six months, so we have data on safety with repeat dosing, and the safety looks quite good. We really believe that we have checked the safety box also now for DME. In addition, there was a significant reduction in treatment burden. Both studies showed that the DURAVYU arms, if in the real world the same type of treatment was applied, we would have on average two fewer injections per year than on-label EYLEA. When you look at the new generation, the second generation anti-VEGFs like high-dose EYLEA and VABYSMO, on average, they appear to be reducing the treatment burden by about one injection a year. Again, if approved and available, we think DURAVYU has the opportunity to do a little bit better than that. Finally, the fluid control. Despite missing the primary endpoint, we control fluid quite well.
That is measured on OCT, central subfield thickness. Normal is around 325 microns. The pooled data from the two trials showed that we were only about 10 microns worse than EYLEA, which is an insignificant amount. I do want to remind everybody, the DURAVYU eyes did gain vision. So it seems to be, of course, a binary result where you either hit the primary or you did not. But in a non-inferiority trial, remember, we just needed to come closer than we came. So when you think about it, if our eyes had gained another letter and a half, or the EYLEA eyes had lost another letter and a half, we would have been non-inferior. So it is not such a binary result in DME.
I think what you need to believe is our drug will work better in DME than it did in this wet AMD population, and that will be enough to get us to non-inferiority.
Remind us on VERONA, just to be clear, that was a monotherapy study?
One single injection. Is that what you're asking?
Yeah. Yes. Like, there's no aflibercept load?
There was no load. There was one injection of aflibercept, and that is another difference from the studies we had run before, all of which included a three-monthly dose load. The way the study was designed, we actually had two doses of DURAVYU, 2.7 milligrams and 1.34 milligrams. At the beginning of the study, all eyes got a shot of EYLEA, and then 30 minutes later, they either got a sham or they got our drug. Over 70% of the DURAVYU eyes went the length of the trial with no other injections, though. I might add, those eyes, if you look at the subgroup analysis for the DME trial, those eyes did great. They gained over 10 letters and had about 120 microns less fluid. The supplement-free eyes, it worked really well in DME.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
